MedPage Today on MSN
Recent developments in prostate cancer
Practice-changing perioperative therapy, chemo-free combo for CSPC, reducing cognitive eff ...
Morning Overview on MSN
A targeted drug won approval for a hard-to-treat form of advanced prostate cancer
Men diagnosed with metastatic hormone-sensitive prostate cancer who carry a specific tumor deficiency now have a targeted ...
Many things are evaluated when doctors are putting a treatment plan together for prostate cancer patients. A new study says one more factor should be considered—chronological age. The study, published ...
The metastatic prostate cancer market is undergoing a major transition from conventional ADT toward combination-based, biomarker-driven, and precision-targeted treatment approaches. While AR pathway ...
Many patients with metastatic castration-resistant prostate cancer are not receiving bone-modifying agents, despite guideline endorsement.
Although it reads like European license plate number, a protein known as ZMYND8 has demonstrated its ability to block metastasis-linked genes in prostate cancer, according to a study at The University ...
The Ellison Medical Institute (EMI) has entered into an exclusive license with UniQuest, the commercialization company of The ...
Development is moving to phase 2 LEGION-100-2a (NCT06533644) across global sites, with planned neoadjuvant prostate studies and expansion concepts in multiple solid tumors. Metastatic ...
Stockholm3 blood test detected 90% of aggressive prostate cancer cases compared to 74% for PSA tests in a study of over ...
For prostate cancer patients with low-volume tumors and metastasis, the median overall survival was 37.13 months. Prostate cancer patients with metastatic disease and low-volume primary tumors appear ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results